Global Pain Relief Medication Market Research Report: By Drug Class (Nonsteroidal Anti-Inflammatory Drugs, Opioids, Others), By Indication (Cancer Pain, Neuropathic Pain, Musculoskeletal Pain, Others) and By Distribution Channel (Hospital and Retail Pharmacies, Online Pharmacies) – Forecast to 2025

Market Forecast

Pain Relief Medication Market held a value of USD 55,275 Million in 2018, at a CAGR of 4.73% during the assessment period of 2019 to 2025.

Market Synopsis

There has been a high level of product approvals by prominent players in the market. There has been an increasing prevalence of chronic and life-threatening diseases, which increases the pool of patients suffering from pain.

Market Influencer

The increasing initiatives by public and private companies boost market growth. The rising number of product launches by major players in the market are likely to act as a substantial contributing factor for the increase in the near future.

Market Drivers

• 
  

  Increasing product approvals. In November 2018, Pfizer Inc. was granted pediatric exclusivity for its product Lyrica (pregabalin), which has been approved in the US for diabetic nerve pain, fibromyalgia, spinal cord injury nerve pain, and pain after shingles in adults.

  
  


• 
  

  Increasing research initiatives

  
  


• 
  

  Rising need for treatment of chronic pain. An approximate of 20% to 24% of patients suffering from diabetic neuropathy go through pain in the US, leading to the growth of this market in the region.

  
  


• 
  

  High prevalence of life-threatening diseases

  
  


• 
  

  Growing awareness regarding the treatment of chronic diseases

  
  


• 
  

  Fast-track approval of drugs

  
  


• 
  

  Increase in the use of combination therapy for the management of pain

  
  

Market Restraints

• Side-effects associated with the drugs


• Increasing product recalls


• Expiry of patents of blockbuster drugs in the pain management area

Segmentation

By Drug Class

• Nonsteroidal Anti-Inflammatory Drugs: These classes of drugs help in reducing inflammation. The largest segment is widely used with a high efficacy rate.


• Opioids: Fastest growing segment as they are considered one of the most effective drug classes for the treatment of chronic pain.


• COX-2 Inhibitors: These are analgesics that were developed to inhibit only the cyclooxygenase enzyme.


• Others: The other segment includes drugs from other classes such as anesthetics, anticonvulsants, and antimigraine drugs.

By Indication

• Cancer Pain: This is expected to be the largest segment, owing to a large number of cancer patients. Cancer pain depends on the type of cancer, the stage of the disease, and the pain threshold of the patient.


• Neuropathic Pain: Neuropathic pain is caused by a lesion or disease of the somatosensory nervous system. Neuropathic pain is often described as burning, tingling, electrical, stabbing or pins and needles.


• Musculoskeletal Pain: Musculoskeletal pain affects the bones, muscles, ligaments, tendons, and nerves. Musculoskeletal pain can be localized in one area or can be widespread throughout the body.


• Inflammatory Conditions: Inflammatory conditions include allergy, coeliac disease, asthma, autoimmune diseases, glomerulonephritis, hepatitis, and inflammatory bowel disease.


• Others: The other segment includes facial pain and migraine.

By Distribution Channel

• Hospital and Retail Pharmacies: Hospital and retail pharmacies are estimated to be the largest segment due to the increasing number of hospitals in-visits.

• Online Pharmacies: Online pharmacies is expected to be the fastest-growing segment due to the increasing awareness and adoption of this type of distribution channel.

By Region

• 
  

  Americas: Americas is estimated to be the largest regional market. Countries such as the US and Canada have well-established research centers and headquarter most of the key companies. This contributes to the growth of the pain relief medication market in this region. An approximate of 20% to 24% of patients suffering from diabetic neuropathy go through pain in the US.

  
  


• 
  

  Europe: The increasing research for novel treatments and the rise in incidence rates of chronic diseases is expected to drive the growth of the pain relief medication market in the European region. An aggregate of Euro 12.3 billion (USD 13.50 billion) is spent annually in the UK for back pain treatment.

  
  


• 
  

  Asia-Pacific: Asia-Pacific is anticipated to be the fastest-growing region in the global pain relief medication market. This region is seeing a surge in the number of people afflicted with pain and the increase in the number of cancer patients. The number of new cancer cases on an annual basis account for almost 4,285,033 in China.

  
  


• 
  

  Middle East & Africa: The smallest market due to limited healthcare infrastructure and limited exposure to innovative products.

  
  

Key Players

• AbbVie Inc. (US)


• Astellas Pharma Inc. (Japan)


• Allergan PLC (Ireland)


• Bayer (Germany)


• Purdue Pharma (US)


• Boehringer Ingelheim International GmbH (Germany)


• Bristol-Myers Squibb (US)


• Eli Lilly and Company (US)


• Mallinckrodt Pharmaceuticals (UK)


• Biogen Idec (US)


• GlaxoSmithKline (UK)


• Pfizer, Inc. (US)


• Sanofi (France)


• Teva Pharmaceutical Industries Ltd (Israel)

Frequently Asked Questions (FAQ) :